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Real-world experience with a Paclitaxel-Coated Balloon for the 
treatment of atherosclerotic infrainguinal arteries: 12-month 
interim results of the BIOLUX P-III registry first year of 
enrolment
Experiência real com balão revestido com paclitaxel para o tratamento de artérias 
infrainguinais ateroscleróticas: resultados após 12 meses do primeiro ano de seleção de 
pacientes para o registro BIOLUX P-III
Marianne Brodmann1, Thomas Zeller2, Johnny Christensen3, Christoph Binkert4, Lubomir Spak5, Henrik Schröder6, 
Paolo Righini7, Giovanni Nano7, Gunnar Tepe8
Abstract
Background: Endovascular management of atherosclerotic infrainguinal arteries recently shifted towards drug eluting 
devices, designed to locally prevent the restenosis process. Numerous clinical studies report an advantage of drug 
coated balloons over uncoated balloon angioplasty in treating lower extremity peripheral artery disease. However, as 
coating and balloon platforms are different, each device requires dedicated clinical evaluations. Objective: The aim 
of the study is to further investigate the safety and effectiveness of a Paclitaxel-Coated Balloon for the treatment of 
atherosclerotic infrainguinal arteries in a real-world setting. Methods: 203 patients out of a final sample of 882 were 
enrolled in this prospective multicenter, observational, all-comers registry during the first 12 months. The primary 
endpoints were major adverse events (defined as procedure or device related death within 30 days post index procedure, 
clinically-driven target lesion revascularization or major target limb amputation) at 6 months and freedom from 
clinically-driven target lesion revascularization at 12 months. Both endpoints were adjudicated by a Clinical Events 
Committee. Results: Mean patient age was 70.2±10.4 years (60.1% male). 47.3% of the patients were diabetic and 67.5% 
had a history of smoking. Severe claudication was reported in 37.4% and 40% had critical limb ischemia. 257 lesions, 
including 13.2% in the infrapopliteal territory, were treated with Passeo-18 Lux (mean lesion length 75.1 mm±69.4, 20% 
occlusions, 76.3% calcified). At 6 months, the rate of major adverse events was 5.5% (95%CI 3.1-9.7). Freedom from 
clinically-driven target lesion revascularization at 12 months was 93.2% (95%CI 89.1-95.8). All causes mortality was 
6.5% (95%CI 3.8-11.0) and overall amputation rate was 4.2% (95%CI 2.1-8.3) at 12 months. Conclusion: In a real-world 
environment, the BIOLUX P-III registry preliminary results confirm the safety and efficacy of the Paclitaxel-Coated 
Passeo-18 Lux balloon as a stand-alone treatment option for atherosclerotic infrainguinal arteries. 
Keywords: Peripheral artery disease; Paclitaxel-Coated Balloon; endovascular therapy.
Resumo
Contexto: O manejo endovascular de artérias infrainguinais ateroscleróticas recentemente tem mudado para dispositivos 
farmacológicos, desenhados para impedir localmente o processo de reestenose. Numerosos estudos clínicos descrevem 
uma vantagem da angioplastia com uso de balões farmacológicos sobre os balões convencionais no tratamento de 
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INTRODUCTION
Peripheral artery disease (PAD) is a global disease 
affecting more than 200 million patients worldwide. 
From 2000 to 2010, the number of patients with PAD 
increased by almost a quarter, and the rate of increase 
in low or middle-income countries was even greater 
(28.7%), because of the rise in life expectancy in 
those populations.1
PAD is caused by atherosclerotic plaques that result 
in stenosis or occlusion of major arteries supplying the 
lower extremities. Obstruction of lower limb arteries 
results in several clinical presentations ranging from 
no symptoms, through life-style limiting intermittent 
claudication (IC), in which patients’ walking ability 
is impaired, to critical limb ischemia (CLI), in which 
arterial flow is so severely reduced it causes chronic 
ischemic rest pain or even ischemic skin lesions, such 
as ulcers or gangrene.1,2
Management of PAD includes mitigation of risk factors 
(smoking cessation, exercise therapy…), medication, 
and ultimately limb revascularization procedures.2 
For a long time, surgery has been considered the gold 
standard treatment for revascularization. However, 
since the late 1990s, with the introduction of new 
endovascular devices, endovascular treatment has 
become the first line therapy for IC and CLI patients.
Percutaneous transluminal angioplasty (PTA) 
or balloon angioplasty is often the initial step in an 
endovascular approach to infrainguinal arterial obstructive 
disease. This technique has been proven to immediately 
restore blood flow safely and effectively. However, 
the vascular inflammation injury resulting from the 
inflated balloon (barotrauma) entails hypertrophic 
neointimal formation through vascular smooth muscle 
cell (VSMC) proliferation and constrictive vascular 
remodeling.3 As a consequence, post-PTA restenosis 
rates are relatively high with 12-month primary 
patency rates of around 52% in well-selected lesions 
from randomized clinical studies.4,5
Stents offer a mechanical scaffold that prevents vessel 
recoil and negative remodeling after PTA. However, 
stent fractures and the presence of a permanent implant 
hindering the vessel’s natural motion prolong vessel 
inflammation and subsequent neointimal proliferation 
within the stent struts. In a recent review, Aghel et al 
reported 12 month primary patency slightly exceeding 
80% for nitinol self-expanding stents and drug eluting 
stents used in moderate-length superficial femoral 
artery (SFA) stenosis.6
Drug coated balloons (DCB) combine balloon 
angioplasty and the release of an anti-proliferative 
drug into the vessel wall during balloon inflation. 
Unlike stenting, DCBs allow the vessel to retain its 
mechanical properties and prevent the restenosis 
caused by barotrauma. In addition, since a permanent 
scaffold is not left behind, all future endovascular 
and surgical intervention options remain available.
Paclitaxel is an antimitotic drug. Its lipophilic 
properties enable rapid absorption by the vessel 
wall upon contact with the coated balloon surface. 
All DCBs currently on the market use paclitaxel as 
anti-proliferative agent in their coating. However, each 
DCB on the market is unique in terms of paclitaxel 
load (2 to 3.5 µg/mm), excipient, balloon material 
and coating technology.
Data from randomized controlled trials revealed 
12 month primary patency ranging from 65 to 82.2%.4,5,7 
A recently published meta-analysis of 11 randomized 
doença arterial periférica dos membros inferiores. No entanto, considerando que as plataformas do revestimento 
farmacológico e dos balões são diferentes, cada dispositivo requer avaliações clínicas específicas. Objetivo: Fazer 
investigação adicional sobre a segurança e eficácia de um balão revestido com paclitaxel para o tratamento de artérias 
infrainguinais ateroscleróticas em um cenário de mundo real. Métodos: 203 pacientes de uma amostra final de 
882 pacientes foram incluídos neste registro prospectivo observacional multicêntrico de inclusão sequencial, durante 
os primeiros 12 meses. Os desfechos primários foram eventos adversos maiores (definidos como morte relacionada 
ao procedimento ou ao dispositivo em até 30 dias após o procedimento-índice, necessidade de revascularização da 
lesão-alvo ou amputação significativa do membro-alvo) em 6 meses e ausência de de revascularização da lesão-alvo 
em 12 meses. Ambos os desfechos foram adjudicados por um comitê de eventos clínicos. Resultados: A idade média 
foi 70,2±10,4 anos (60,1% sexo masculino). 47,3% dos pacientes eram diabéticos, e 67,5% tinham história de tabagismo. 
Claudicação severa foi relatada em 37,4%, e 40% apresentava isquemia crítica de membro. 257 lesões, incluindo 13,2% 
em território infrapoplíteo, foram tratadas com o balão Passeo-18 Lux (comprimento médio das lesões 75,1 mm±69,4, 
20% oclusões, 76,3% calcificadas). Aos 6 meses, a taxa de eventos adversos maiores foi de 5,5% (95%CI 3,1-9,7). A ausência 
de revascularização da lesão-alvo aos 12 meses foi de 93,2% (95%CI 89,1-95,8). Mortalidade por todas as causas foi 
de 6,5% (95%CI 3,8-11,0) e a taxa geral de amputação foi de 4,2% (95%CI 2,1-8,3) aos 12 meses. Conclusão: Em um 
cenário de mundo real, os resultados preliminares do registro BIOLUX P-III confirmam a segurança e eficácia do balão 
revestido com paclitaxel Passeo-18 Lux como opção de tratamento único para artérias infrainguinais ateroscleróticas. 
Palavras-chave: doença arterial periférica; balão revestido com paclitaxel; terapia endovascular.
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controlled trials demonstrated an advantage of 
DCB compared to uncoated balloon angioplasty in 
treating lower extremity peripheral artery disease, as 
indicated by improved primary vessel patency, and 
late lumen loss for up to two years and target lesion 
revascularization and binary restenosis rates for up to 
five years.8 However, it is well known that the coating 
technology plays a major role in the DCB performance. 
In particular, the excipient has to maintain the coating 
integrity during balloon tracking to the target lesion, 
while allowing the release of a therapeutic dose of 
the drug to the vessel upon inflation and contact with 
the vessel wall.
The Passeo-18 Lux DCB (Biotronik AG, Buelach, 
Switzerland) obtained CE-marking in Europe in 
January 2014. It combines the Passeo-18 PTA balloon 
catheter with a coating matrix composed of paclitaxel 
(3 mcg/mm2) and butyryl-tri-n-hexyl citrate (BTHC) 
as an inert excipient.
The safety and efficacy of the Passeo-18 Lux DCB 
for the treatment of PAD have been investigated in two 
first -in-man randomized (1:1) controlled studies,9,10 
Passeo-18 PTA versus Passeo-18 Lux. The BIOLUX 
P-I trial9 and BIOLUX P-II trial10 results report 
safety and efficacy of the Passeo-18 Lux DCB for the 
treatment of atherosclerotic lesions in respectively, 
femoropopliteal and infrapopliteal arteries. Results 
are consistent with previously reported DCB trials 
with the same anti-proliferative drug.
The purpose of the BIOLUX P-III all comers global 
registry (ClinicalTrials.gov; identifier: NCT02276313) 
is to confirm the first-in-man data of Passeo-18 Lux 
DCB in a real-world population of patients with 
obstructive disease of the infrainguinal arteries.
In this article, we will present the 12-month results 
for subjects included during the first year of enrolment.
METHODS
Study design and study population
BIOLUX P-III is a prospective, international, 
multicenter, all comers registry aiming to confirm 
the safety and effectiveness of the Passeo-18 Lux 
drug-coated balloon for treatment of atherosclerotic 
disease in the infrainguinal arteries in daily clinical 
practice. Furthermore, analysis of dedicated pre-defined 
patient subgroups, including, inter alia, diabetes, 
complex TASC C & D lesions and infrapopliteal 
lesions are planned.
All patients with lesion(s) in the infrainguinal 
arteries suitable for endovascular therapy treated with, 
or scheduled to be treated with, the Passeo-18 Lux 
DCB qualify for the registry. At least 700 patients 
were to be enrolled. The cohort has been extended to 
882 patients to reach pre-specified subgroups sizes. 
Main exclusion criteria are failure to successfully 
cross the target lesion with a guide wire (successful 
crossing means tip of the guide wire distal to the target 
lesion) and absence of flow limiting dissections or 
perforations prior to DCB treatment.
Patients underwent percutaneous intervention with 
the Passeo-18 Lux DCB as per its instructions for use, 
according to standard of care and the investigator’s 
standard clinical practice. Therefore, use of adjunctive 
endovascular devices or techniques (cutting balloon, 
atherectomy, stents) was not restricted. The numbers 
of lesions treated with the Passeo-18 Lux was at the 
investigator’s discretion and according to the clinical 
practice at the site.
The study, which was approved by the respective 
independent ethical committees, is conducted 
according the Declaration of Helsinki, as well as 
parts of International Conference on Harmonization 
Good Clinical Practices (ICH-GCP), and ISO 14155 
applicable to registries. All patients provided written 
informed consent.
Monitoring and data analysis is organized by the 
trial’s sponsor, Biotronik AG (Buelach, Switzerland). 
The trial is registered on the National Institutes 
of Health website (ClinicalTrials.gov; identifier 
NCT02276313).
Study devices
The Passeo-18 Lux DCB, CE-marked in Europe 
since January 2014, is identical to the commercially 
available Passeo-18 PTA balloon catheter with the 
addition of a homogeneous coating of paclitaxel as 
the lipophilic anti-proliferative substance (3 μg of 
paclitaxel per mm2 balloon surface). The paclitaxel 
is incorporated in a delivery matrix of the excipient 
BTHC, which binds the drug into a microcrystalline 
structure to improve uptake into the vessel wall. 
BTHC degrades to citric acid and alcohol in the 
body. The balloons are available in diameters of 
2.5 to 7.0 mm and lengths of 40 to 120 mm.
Endpoints and definitions
The primary endpoints are freedom from Major 
Adverse Events (MAE) within 6 months post-index 
procedure and freedom from clinically driven target 
lesion revascularization (CD TLR, defined as any 
re-intervention performed for ≥ 50% diameter stenosis 
[visual estimate] at the target lesion after documentation 
of recurrent clinical symptoms of the patient) within 
12 months post-index procedure.
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All MAE and CD TLR were adjudicated by an 
independent Clinical Events Committee (CEC).
Secondary endpoints are freedom from MAE 
at 12 and 24 months; freedom from CD TLR at 
6 and 24 months; freedom from CD target vessel 
revascularization at 6, 12, and 24 months; primary 
patency at 12 and 24 months; change in mean 
Ankle Brachial Index (ABI) at 6, 12, and 24 months 
(and prior to re-intervention); change in Rutherford 
classification at 6, 12, and 24 months (and prior to 
any re-intervention) compared to the pre-procedure 
Rutherford classification; rates of freedom from major 
and minor target limb amputation at 6, 12, and 24 months 
and overall amputation rate; Patient-reported 
outcomes assessment: Pain scale (Wong-Baker Face) 
and Walking Impairment Questionnaire (WIQ) at 
6, 12, and 24 months, compared to the pre-procedure 
score; device success; technical success; procedural 
success.
For baseline lesion length, consecutive multiple 
single lesions with a healthy segment ≤ 2 cm between 
them were considered as one lesion.
MAE are defined as composite of device- and 
procedure-related mortality through 30 days, major 
target limb amputation, and clinically-driven target 
lesion revascularization. Major amputations were 
above the ankle.
Primary patency was defined as freedom from > 50% 
restenosis in the target lesion as indicated by a duplex 
ultrasound peak systolic velocity ratio (PSVR) > 2.5 
or by visual assessment of an angiogram with no 
clinically-driven re-intervention.
Technical success was defined as successful 
completion of the endovascular procedure and 
immediate morphological success with ≤ 50% residual 
diameter reduction of the treated lesion as determined 
by visual estimation. Device success was defined as 
successful delivery, inflation, deflation, and retrieval 
of the Passeo-18 Lux DCB. Procedural success was 
defined as technical and device success with no 
occurrence of any MAE during the hospital stay.
Statistical analysis
Endpoint analysis was performed on data 
available from patients recruited during the first 
year of enrolment. Considering the observational 
registry design, BIOLUX P-III does not involve a 
hypothesis-driven sample size estimation. However, 
assuming a primary outcome freedom from CD TLR 
rate of 90% at 12 months, a sample size larger than 
150 subjects will provide an acceptable error in the 
estimate of ± 5% allowing sufficient precision for 
interim- and sub-group analysis.
For quantitative variables, the mean values, 
standard deviation, maximum and minimum were 
determined. A two-sided 95% confidence interval 
(95%CI) for the mean was calculated when relevant. 
For qualitative variables, absolute and relative 
frequencies were determined. For proportions, exact 
Binomial two-sided 95%CI was calculated when 
relevant. The rate of freedom from CD TLR and MAE 
and its individual components were estimated using 
the Kaplan-Meier method. Estimates are presented 
with the 95%CI. The chi-square or Fisher’s exact tests 
were used to compare binary variables, and Student’s 
t test or the Wilcoxon-Mann-Whitney test were used 
to compare continuous variables for independent 
samples. Follow-up comparisons were performed 
using Wilcoxon-signed-rank tests. Standard error was 
calculated using Greenwood’s formula. Statistical 
calculations were performed using SAS software 
(version 9.1.3; SAS Institute, Inc, Cary, NC, USA).
RESULTS
Patient population
Between October 2014 and September 2015, 
203 patients (122 men) out of 882 for the full cohort; 
mean age 70.2±10.4 years with 257 lesions were 
treated with Passeo-18 Lux at 20 centers worldwide 
(Table 1, Figure 1).
Figure 1. Patients flow chart.
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Almost half of the patients (47.3%, 96 patients) 
were diabetic and two-thirds (67.5%, 138 patients) 
had a history of smoking. Severe claudication was 
reported in 37.4% (76 patients) with 40% (81 subjects) 
CLI (Rutherford class > 3). Demographics and 
comorbidities are summarized in Table 2.
Procedure and lesion details
Target lesion baseline characteristics and procedure 
details are summarized in Table 2. The average lesion 
length was 75.1 mm±69.4 and 20% of lesions were 
occluded.
The majority of lesions were located in the 
superficial femoral artery (56.4%, 145/257), almost 
a quarter (23%, 59/257) in the popliteal artery, and 
13.2% (34/257) were in the infrapopliteal territory. 
More than three-quarters of the lesions were calcified, 
including almost 12% that were heavily calcified. 
Device success was 98.5% and technical success was 
achieved in 98.4%. Procedural success was 95.6% 
and 13.2% of the lesions required at least one stent.
Procedure and lesion details are presented in 
Tables 3 and 4.
Primary endpoints
The CEC adjudicated MAE rate was 5.5% 
(95%CI 3.1-9.7) at 6 months (180 days), and 10.1% 
(95%CI 6.5-15.4) at 12 months (365 days). Freedom 
from clinically-driven TLR at 12 months, as adjudicated 
by the CEC, was 93.2% (95%CI 89.1-95.8) (Figure 2). 
Only one patient died from an unknown cause within 
30 days post index procedure. All-causes mortality rate 













Table 2. Baseline patient demographics.
Total = 203
n (%), if not indicated 
otherwise





Current Smokers 52 (38.0%)
History of PAOD 120 (59.1%)
Previous PVI/Surgeries 115 (56.7%)
Diabetes 96 (47.3%)
Coronary artery disease 80 (39.4%)
Cerebrovascular disease 49 (24.1%)
Rutherford classification (n = 203) n (%)
1-mild claudication 1 (0.5%)
2-moderate claudication 27 (13.3%)
3-severe claudication 76 (37.4%)
4-ischemic rest pain 18 (8.9%)
5-minor tissue loss 47 (23.2%)
6-major tissue loss 16 (7.9%)
Unknown 18 (8.9%)
ABI (n = 129 limbs) (mean ± SD) 0.7±0.2
Table 3. Lesion characteristics.
n = 257 lesions
Lesion Length, mm (mean ± SD) 75.1±69.4
Lesion Length distribution
≤ 100 mm 202 (78.6%)
> 100 mm and ≤ 150 mm 27 (10.5%)
> 150 mm and ≤ 200 mm 12 (4.7%)
> 200 mm 15 (5.8%)
Unknown 1 (0.4%)
Reference Vessel Diameter, mm (mean ± SD) 4.7±1.0










Heavily calcified 30 (11.7%)
Unknown 1 (0.4)
De Novo Lesion (n, %) 135 (52.5%)
Re-Stenosis (n, %) 37 (14.4%)
In Stent Restenosis (n, %) 31 (12.1%)
Occlusion (n, %) 54 (21.0%)
Common Femoral 1 (0.4%)
Superficial Femoral Artery 145 (56.4%)
Femoropopliteal 9 (3.5%)
Popliteal Artery 59 (23.0%)
Tibioperoneal Trunk 9 (3.5%)
Anterior Tibial Artery 13 (5.1%)
Posterior Tibial Artery 3 (1.2%)
Peroneal Artery 3 (1.2%)
Combination of Infrapopliteal Arteries 6 (2.3%)
Other (Bypass, Iliac) 9 (3.5%)
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was 6.5% (95%CI 3.8-11.0) at 12 months. Two major 
amputations (1.0% [95%CI 0.2-3.9]) occurred at 
18 and 75 days post index procedure in patients with 
baseline Rutherford categories of 6 and 5. Overall 
amputation rate, including minor amputations, was 
4.2% (95%CI 2.1-8.3) at 12 months. Safety and 
effectiveness outcomes are detailed in Table 5 and 
Figure 2.
Secondary endpoints
Primary patency was 85.4% (95%CI 80.2-89.4) at 
12 months. Change in ABI at 12 month compared to 
baseline was 0.17±0.26 (p < 0.001). The vast majority 
of 82.7% of patients improved significantly by at 
Table 4. Procedure details.
Device success (n = 326 devices) 98.5% (321/326)
Technical success (n = 257 lesions) 98.4% (253/257)
Vessel preparation 70.8% (182/257)
POBA 63.0% (162/257)
Cutting/scoring balloon 4.7% (12/257)
Rotational thrombectomy 2.3% (6/257)
Atherectomy 0.8% (2/257)
Combination DCB + Stents 13.2% (34/257)
Procedural success (n = 203) 95.6% (194/203)
Device success: successful delivery, inflation, deflation, and retrieval of 
the Passeo-18 Lux DCB. Technical success: successful completion of the 
endovascular procedure and immediate morphological success with ≤ 50% 
residual diameter reduction of the treated lesion as determined by visual 
estimation. Procedural success: technical and device success without the 
occurrence of any MAE during the hospital stay.
Figure 2. (A) Twelve-month freedom from clinically-driven target lesion revascularization; (B) Twelve-month Major Adverse Event Rate.
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least one Rutherford category at 12 months compared 
to baseline whereas 75.4% improved significantly 
according to the Pain Scale (Figure 3).
Key secondary outcomes details are included in 
Table 5.
DISCUSSION
BIOLUX P-III is the first all-comers registry 
to report results for endovascular treatment of 
atherosclerotic infrainguinal arteries including tibial 
arteries with a drug-coated balloon, in a real-word 
setting including patients suffering from PAD at 
Rutherford categories 5 and 6. Published data from 
other global registries11-13 are limited to femoropopliteal 
arteries and patients with Rutherford classes 1 to 4.
In the BIOLUX P-I trial,9 a prospective, 
international, multicenter, randomized (1:1) controlled 
trial, 60 patients with stenosis or occlusion of the 
superficial femoral artery (SFA) and popliteal 
arteries were treated with either Passeo-18 PTA or 
Passeo-18 Lux DCB. At 6 months, patients treated 
with the Passeo-18 Lux DCB had a significantly 
lower late lumen loss (0.51±0.72 vs. 1.04±1.00 mm, 
p = 0.033) and binary restenosis (11.5% vs. 34.6%, 
p = 0.048) than the control PTA group, respectively. 
There were no deaths and 1 minor amputation was 
observed in the DCB group compared with 2 deaths 
and 2 minor amputations in the PTA group. No major 
amputations or thrombosis occurred in either group.
In the BIOLUX P-II trial,10 a prospective, 
international, multicenter, randomized (1:1) controlled 
first-in-man study, 72 patients suffering from 
claudication or critical limb ischemia, and stenosis, 
restenosis or occlusion of the infrapopliteal arteries 
were treated with Passeo-18 PTA or Passeo-18 Lux 
DCB. The primary safety endpoint, rate of major 
adverse events (MAE), (a composite of all-cause 
mortality, target extremity major amputation, target 
lesion thrombosis, and target vessel revascularization 
at 30 days), was 0% in the Passeo-18 Lux DCB group 
versus 8.3% in the PTA group (p = 0.239). Patency 
loss at 6 months, was 17.1% in the DCB group 
versus 26.1% in the PTA group (p = 0.298). Major 
amputations of the target extremity occurred in 3.3% 
in the Passeo-18 Lux DCB group versus 5.6% in the 
PTA group at 12 months.
The BIOLUX P-III all-comers registry interim 
12-month results confirm Passeo-18 Lux safety and 
efficacy. Only two major amputations occurred in 
patients with baseline Rutherford categories of 6 and 5. 
At 12 months, freedom from clinically-driven TLR was 
93.2% and the MAE rate was 10.1%. These outcomes 
are comparable to previous Passeo-18 Lux first-in-
man studies9,10 and currently available data from real 
world registries on the use of DCBs in femoropopliteal 
arteries which report 12-month fCD TLR up to 94%.11-13 
The use of additional devices (atherectomy, scoring 
balloons, stents) was not restricted in BIOLUX P-III. 
Table 5. Key outcomes.
6 months 12 months
MAE* 5.5% (11) 10.1% (19)
Death 1 1
CD TLR 8 16
Major amputation 2 2
CD TLR 8 16
All causes of death 10 13
Amputations (All)† 6 8
Major amputations 2 2
Minor amputations 5 7
Change in ABI/TBI  
(mean ± SD)
0.23±0.30 0.17±0.26
Change in Rutherford classification 
(mean ± SD)
-2.39±1.74 -2.45±1.90
*Data are given as the Kaplan-Meier estimated percentage; †First event in time.
Figure 3. Change in Rutherford classification (12 months 
vs. baseline) – paired data (n = 137 subjects). (A) Negative 
figures correspond to Rutherford classification improvement. 
For instance “-3” correspond to an improvement from RC 4 
at baseline to RC  1 at 12 months. (B) Change in Pain Scale 
(12 months vs baseline).
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Yet, despite 76.3% of lesions being calcified (and 
11.7% heavily calcified), only 13.2% of the lesions 
required a stent, compared to about 25% in other 
registries.12,13 These results support use of Passeo-18 
Lux as a stand-alone treatment for atherosclerotic 
infrainguinal lesions, thus reducing the need for 
durable implants even when lesions are calcified. 
Moreover, in a cohort of patients in which 40% of 
patients had CLI (including 30% with Rutherford 
class 5 or 6), the BIOLUX P-III all-comers data 
demonstrate statistically significant improvements in 
Rutherford classification and pain score, with 82.7% 
and 75.4% improvement at 12 months respectively.
In view of resource constraints and soaring health 
care costs, the need for cost-effective therapies is 
critical. In Brazil, for instance, health care costs 
associated with PAD endovascular revascularization 
increased 92% between 2008 and 2012.14 Several 
studies15-17 have suggested DCB’s cost-effectiveness 
for the treatment of atherosclerotic femoropopliteal 
arteries compared to PTA. However, each DCB is 
different and must be evaluated in randomized and 
real-world clinical investigations to demonstrate their 
performance and safety. Passeo-18 Lux DCB safety 
and effectiveness are supported by a robust set of 
clinical evidence comparable to other devices with 
published clinical data, as indicated by the 12-month 
CD TLR rate (6.8%) in particular. Real-world evidence 
has demonstrated consistent results and improvement 
in clinical outcomes such as Rutherford classification 
and pain scale.
Study limitations
Lack of randomization and control group could 
be seen as limitations. However, unlike randomized 
studies, real-world studies are not restricted to low 
risk patients who are most likely to benefit from the 
treatment. To comply with standards of care, neither 
angiographic nor duplex ultrasound were mandated. 
Hence, the efficacy secondary endpoint, primary 
patency, could not be systematically assessed. Data 
published here are not complete and only concern 
the 12-month results of patients included during the 
first year of enrolment.
CONCLUSION
In a real-world environment, the BIOLUX P-III 
All-Comers registry preliminary results confirm the safety 
and efficacy of Passeo-18 Lux DCB as a stand-alone 
treatment option for PAD in infrainguinal arteries. 
Those findings are encouraging and consistent with 
results deriving from first-in-man RCTs. Upcoming 
full cohort data, subgroups analysis (diabetes, female 
sex, CLI, infrapopliteal lesions) and longer-term, 
24-month, follow-up data will enable determination of 
the benefit of Passeo-18 Lux in high-risk populations 
and complex lesions and how this benefit is sustained 
over time.
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